Bone Biologics (NASDAQ:BBLG) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Bone Biologics (NASDAQ:BBLG) in a research note published on Tuesday morning,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of Bone Biologics from a “sell” rating to a “hold” rating in a report on Sunday, September 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bone Biologics has a consensus rating of “Sell”.

Bone Biologics Price Performance

Shares of NASDAQ BBLG opened at $2.57 on Tuesday. The company’s fifty day moving average price is $2.31 and its 200 day moving average price is $3.52. Bone Biologics has a 1 year low of $1.95 and a 1 year high of $13.80.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.75). As a group, analysts anticipate that Bone Biologics will post -5 earnings per share for the current year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.